Business Today

Weight-Loss Drug Sales Slow In May, Mounjaro Still Leads The Pack

India's fast-growing weight-loss drug market is showing signs of moderation after a sharp surge in recent months. New data reveals that sales growth of semaglutide and GLP-1 therapies slowed significantly in May compared to April, even as overall demand remains robust. Industry experts say the next phase of growth will depend on the availability of affordable generic alternatives, wider adoption beyond major cities, and increasing awareness among patients seeking obesity and metabolic health treatments. With drugs such as Mounjaro, Wegovy and Ozempic driving demand, pharma companies are betting big on what could become one of India's largest healthcare opportunities over the next few years.